Equities Analysts Issue Forecasts for LSTA FY2024 Earnings

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – HC Wainwright lifted their FY2024 EPS estimates for shares of Lisata Therapeutics in a research note issued on Thursday, November 21st. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($2.64) per share for the year, up from their prior estimate of ($2.99). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Lisata Therapeutics’ Q4 2024 earnings at ($0.79) EPS, FY2025 earnings at ($1.83) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.26) EPS.

Lisata Therapeutics Price Performance

Lisata Therapeutics stock opened at $2.88 on Monday. The company’s 50-day moving average is $2.93 and its 200 day moving average is $3.09. Lisata Therapeutics has a 1-year low of $2.05 and a 1-year high of $3.83. The firm has a market capitalization of $24.18 million, a P/E ratio of -1.15 and a beta of 1.22.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.16. During the same period in the prior year, the company earned ($0.65) earnings per share.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP lifted its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. 8.94% of the stock is owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.